Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling.

Fresnais M, Muck A, Majewsky M, Statz B, Krausert S, Benzel J, Castel D, Le Dret L, Pfister S, Haefeli WE, Burhenne J, Longuespée R.

J Am Soc Mass Spectrom. 2020 Jan 23. doi: 10.1021/jasms.0c00005. [Epub ahead of print]

PMID:
31971791
2.

Advances in Clinical Pharmacology: Rapid Detection of Small Molecules in Solid Samples at Atmospheric Pressure Using Desorption Electrospray Ionization.

Fresnais M, Haefeli WE, Burhenne J, Longuespée R.

OMICS. 2020 Jan;24(1):53-54. doi: 10.1089/omi.2019.0195. Epub 2019 Dec 19. No abstract available.

PMID:
31855509
3.

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

van Tilburg CM, Milde T, Witt R, Ecker J, Hielscher T, Seitz A, Schenk JP, Buhl JL, Riehl D, Frühwald MC, Pekrun A, Rossig C, Wieland R, Flotho C, Kordes U, Gruhn B, Simon T, Linderkamp C, Sahm F, Taylor L, Freitag A, Burhenne J, Foerster KI, Meid AD, Pfister SM, Karapanagiotou-Schenkel I, Witt O.

Clin Epigenetics. 2019 Dec 10;11(1):188. doi: 10.1186/s13148-019-0775-1.

4.

Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents.

Gade C, Sverrisdóttir E, Dalhoff K, Sonne J, Johansen MØ, Christensen HR, Burhenne J, Mikus G, Holm JC, Lund TM, Holst H.

Clin Pharmacokinet. 2019 Nov 19. doi: 10.1007/s40262-019-00838-1. [Epub ahead of print]

PMID:
31745864
5.

Rapid drug detection in whole blood droplets using a desorption electrospray ionization static profiling approach - a proof-of-concept.

Fresnais M, Haefeli WE, Burhenne J, Longuespée R.

Rapid Commun Mass Spectrom. 2020 Mar 30;34(6):e8614. doi: 10.1002/rcm.8614.

PMID:
31657865
6.

Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.

Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G.

Sci Rep. 2019 Oct 10;9(1):14635. doi: 10.1038/s41598-019-51279-6.

7.

Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.

Russo A, Paret C, Alt F, Burhenne J, Fresnais M, Wagner W, Glaser M, Bender H, Huprich S, Harter PN, Filipski K, Lehmann N, Backes N, Roth L, Seidmann L, Sommer C, Brockmann MA, Pietsch T, Neu MA, Wingerter A, Faber J.

Int J Mol Sci. 2019 Aug 30;20(17). pii: E4267. doi: 10.3390/ijms20174267.

8.

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.

Huppertz A, Grond-Ginsbach C, Dumschat C, Foerster KI, Burhenne J, Weiss J, Czock D, Purrucker JC, Rizos T, Haefeli WE.

BMC Pharmacol Toxicol. 2019 Aug 29;20(1):53. doi: 10.1186/s40360-019-0331-9.

9.

Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range.

Vay M, Sauter M, Mikus G, Burhenne J.

Bioanalysis. 2019 Aug;11(16):1459-1467. doi: 10.4155/bio-2019-0129. Epub 2019 Aug 14.

PMID:
31411489
10.

An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma.

Sauter M, Uhl P, Foerster KI, Mohr I, Höne RT, Merle U, Burhenne J, Haefeli WE.

J Pharm Biomed Anal. 2019 Sep 10;174:633-638. doi: 10.1016/j.jpba.2019.06.015. Epub 2019 Jun 27.

PMID:
31279892
11.

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2019 Oct;85(10):2310-2320. doi: 10.1111/bcp.14040. Epub 2019 Aug 9.

PMID:
31222796
12.

Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.

Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, Weiss J, Zorn M, Haefeli WE, Czock D.

Clin Pharmacol Ther. 2019 Dec;106(6):1290-1298. doi: 10.1002/cpt.1529. Epub 2019 Jul 10.

PMID:
31152598
13.

Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J.

Eur J Pharm Sci. 2019 Jul 1;135:77-82. doi: 10.1016/j.ejps.2019.05.010. Epub 2019 May 16.

PMID:
31102650
14.

An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.

Sauter M, Uhl P, Majewsky M, Fresnais M, Haefeli WE, Burhenne J.

Bioanalysis. 2019 May;11(9):887-898. doi: 10.4155/bio-2018-0322. Epub 2019 May 16.

PMID:
31094209
15.

Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A.

Geist M, Bardenheuer H, Burhenne J, Mikus G.

Palliat Med. 2019 Jul;33(7):850-855. doi: 10.1177/0269216319843629. Epub 2019 Apr 26.

PMID:
31023150
16.

Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.

Geist MJP, Siller N, Egerer G, Bardenheuer H, Burhenne J, Mikus G.

Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):117-122. doi: 10.1111/bcpt.13232. Epub 2019 Apr 15.

PMID:
30916851
17.

Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.

Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D.

Br J Clin Pharmacol. 2019 Jul;85(7):1528-1537. doi: 10.1111/bcp.13934. Epub 2019 May 9.

PMID:
30912163
18.

Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.

Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE.

Clin Pharmacokinet. 2019 Sep;58(9):1155-1163. doi: 10.1007/s40262-019-00749-1.

PMID:
30828771
19.

Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro.

Schäfer J, Burhenne J, Weiss J, Theile D.

Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):461-466. doi: 10.1007/s00210-018-01602-1. Epub 2018 Dec 15.

PMID:
30554340
20.

Obesity-induced CYP2E1 activity in children.

Gade C, Dalhoff K, Petersen T, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H.

Br J Clin Pharmacol. 2019 Feb;85(2):458-459. doi: 10.1111/bcp.13813. Epub 2018 Dec 9. No abstract available.

21.

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E.

Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.

22.

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.

Huppertz A, Werntz L, Meid AD, Foerster KI, Burhenne J, Czock D, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2018 Dec;84(12):2903-2913. doi: 10.1111/bcp.13757. Epub 2018 Oct 11.

23.

Identification, Biosynthesis, and Decapping of NAD-Capped RNAs in B. subtilis.

Frindert J, Zhang Y, Nübel G, Kahloon M, Kolmar L, Hotz-Wagenblatt A, Burhenne J, Haefeli WE, Jäschke A.

Cell Rep. 2018 Aug 14;24(7):1890-1901.e8. doi: 10.1016/j.celrep.2018.07.047.

24.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

25.

Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay.

Foerster KI, Huppertz A, Meid AD, Müller OJ, Rizos T, Tilemann L, Haefeli WE, Burhenne J.

Anal Chem. 2018 Aug 7;90(15):9395-9402. doi: 10.1021/acs.analchem.8b02046. Epub 2018 Jul 17.

PMID:
29985592
26.

Higher chlorzoxazone clearance in obese children compared with nonobese peers.

Gade C, Dalhoff K, Petersen TS, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H.

Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. doi: 10.1111/bcp.13602. Epub 2018 Jun 3.

27.

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.

Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. No abstract available.

28.

Reply to Truffot et al.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE.

Clin Infect Dis. 2018 May 2;66(10):1644-1646. doi: 10.1093/cid/cix1099. No abstract available.

PMID:
29385537
29.

Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS.

Majewsky M, Castel D, Le Dret L, Johann P, Jones DT, Pfister SM, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2018 Mar 20;151:151-158. doi: 10.1016/j.jpba.2017.12.056. Epub 2017 Dec 28.

PMID:
29328982
30.

In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial.

Geist MJP, Bardenheuer HJ, Burhenne J, Mikus G.

J Palliat Med. 2018 May;21(5):686-688. doi: 10.1089/jpm.2017.0461. Epub 2018 Jan 12.

PMID:
29327978
31.

Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy.

Foerster KI, Huppertz A, Müller OJ, Rizos T, Tilemann L, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2018 Jan 30;148:238-244. doi: 10.1016/j.jpba.2017.10.011. Epub 2017 Oct 16.

PMID:
29055248
32.

A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T.

Cancer Chemother Pharmacol. 2017 Nov;80(5):1013-1026. doi: 10.1007/s00280-017-3447-x. Epub 2017 Oct 7.

33.

Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.

Bajraktari G, Burhenne J, Bugert P, Haefeli WE, Weiss J.

Biochem Pharmacol. 2017 Dec 1;145:54-63. doi: 10.1016/j.bcp.2017.08.026. Epub 2017 Sep 28.

PMID:
28964803
34.

Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.

Clemens J, Welti L, Schäfer J, Seckinger A, Burhenne J, Theile D, Weiss J.

Oncol Lett. 2017 Sep;14(3):3185-3192. doi: 10.3892/ol.2017.6560. Epub 2017 Jul 8.

35.

[Erratum to: Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism].

Wolfert C, Merbach M, Stammler G, Emrich O, Meid AD, Burhenne J, Blank A, Mikus G.

Schmerz. 2017 Oct;31(5):515. doi: 10.1007/s00482-017-0236-8. German. No abstract available.

PMID:
28674828
36.

Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension.

Enderle Y, Witt L, Wilkens H, Grünig E, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2017 Sep 5;143:291-298. doi: 10.1016/j.jpba.2017.05.052. Epub 2017 Jun 10.

PMID:
28628863
37.

Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.

Burhenne J, Liu L, Heilig CE, Meid AD, Leisen M, Schmitt T, Kasper B, Haefeli WE, Mikus G, Egerer G.

Cancer Chemother Pharmacol. 2017 Aug;80(2):433-439. doi: 10.1007/s00280-017-3357-y. Epub 2017 Jun 13.

PMID:
28612091
38.

[Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism].

Wolfert C, Merbach M, Stammler G, Emrich O, Meid AD, Burhenne J, Blank A, Mikus G.

Schmerz. 2017 Oct;31(5):516-523. doi: 10.1007/s00482-017-0228-8. German. Erratum in: Schmerz. 2017 Jul 3;:.

PMID:
28597312
39.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

40.

The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.

Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf S, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE.

Clin Pharmacol Ther. 2018 Feb;103(2):341-348. doi: 10.1002/cpt.744. Epub 2017 Jun 21.

PMID:
28543042
41.

Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE.

Clin Infect Dis. 2017 Sep 15;65(6):1033-1036. doi: 10.1093/cid/cix443.

PMID:
28505263
42.

Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry.

Suzuki Y, Witt L, Mier W, Mikus G, Markert C, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2017 Aug 5;142:84-90. doi: 10.1016/j.jpba.2017.04.038. Epub 2017 Apr 29.

PMID:
28500979
43.

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.

Schäfer J, Welti L, Seckinger A, Burhenne J, Theile D, Weiss J.

Cancer Chemother Pharmacol. 2017 Jul;80(1):71-79. doi: 10.1007/s00280-017-3335-4. Epub 2017 May 12.

PMID:
28500557
44.

Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.

Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE.

Respiration. 2017;94(1):26-37. doi: 10.1159/000470916. Epub 2017 May 12.

45.

Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.

Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, Mikus G.

Br J Clin Pharmacol. 2017 Sep;83(9):1954-1965. doi: 10.1111/bcp.13297. Epub 2017 May 18.

46.

Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.

Harnoss JM, Platzer LK, Burhenne J, Radhakrishnan P, Cai J, Strowitzki MJ, Weiss J, Ritter AS, Mollenhauer M, Schmidt T, Ulrich A, Haefeli WE, Schneider M.

Ann Surg. 2017 Apr;265(4):782-791. doi: 10.1097/SLA.0000000000001696.

PMID:
28266966
47.

Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.

Mikus G, Heinrich T, Bödigheimer J, Röder C, Matthee AK, Weiss J, Burhenne J, Haefeli WE.

J Clin Pharmacol. 2017 Jul;57(7):899-905. doi: 10.1002/jcph.879. Epub 2017 Feb 14.

PMID:
28194792
48.

The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.

Weinheimer M, Fricker G, Burhenne J, Mylius P, Schubert R.

Eur J Pharm Sci. 2017 Oct 15;108:13-22. doi: 10.1016/j.ejps.2016.08.055. Epub 2016 Aug 30.

PMID:
27590127
49.

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Medicine (Baltimore). 2016 Aug;95(34):e4631. doi: 10.1097/MD.0000000000004631.

50.

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.

Dettmer S, Theile D, Schäfer J, Seckinger A, Burhenne J, Weiss J.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Oct;389(10):1091-101. doi: 10.1007/s00210-016-1276-9. Epub 2016 Jul 15.

PMID:
27422413

Supplemental Content

Loading ...
Support Center